Advanced Biotech Delivers Precise Disease Detection
Accurate Disease Detection with Advanced Biotech Diagnostics by @antgrasso #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/71nTNGOdDQ
Safety and Efficacy Assessments Created to Prevent Thalidomide Disaster
The current system of assessing safety and efficacy was literally invented to avoid the best thalidomide 😃
New TB Vaccines Safe, Effective for Children, Not All Forms
Two new tuberculosis vaccines demonstrated safety and immune response in a large Indian trial, but did not provide broad protection against all TB forms; notable efficacy was observed against extrapulmonary TB and in children. tuberculosis
LP(a)-Lowering Drugs Poised as Pharma’s Next Breakthrough
The next big thing in pharma over the next few years - drugs to reduce LP(a). https://t.co/2rmLcAFGp1
Scientists Advance mRNA Immunotherapies for Cancer, Funding Lags
Now in addition to our @TexasChildrens @BCM_TropMed protein vaccines for global health, our scientists are refining the mRNA technology for new immunotherapies for pancreatic cancer and triple negative breast cancer, if only the grant support would hold… https://t.co/NEgq6DX4qz
Interpretability Becomes New Scalability in Synthetic Biology
One of the most clarifying conversations we've had about where biotech should go next. Krish Ramadurai of @aixventureshq argues interpretability is the new scalability, and that the founders who build mechanistic, measurable platforms will define the next era of synthetic biology. He...
AI‑Native Platforms Treat Genome Like Code, Transform Biotech
Investor Liliana Nordbakk believes the genome behaves like code and AI-native biology platforms will transform biotech. Excited to have her speaking at #SynBioBeta2026. Visit the SynBioBeta website to read the full article. https://t.co/3WOSXsz1zy
Polygenic Scores Make Parental Genetic Choices More Intentional
Parents already make genetic decisions about the traits of their kids when they select a partner. Now those choices are becoming more conscious. @herasight is building polygenic scores that predict traits and diseases across diverse ancestries. Looking forward to hearing @JonathanAnomaly...
Family's Funding Fuels Hope for New Dementia Therapies
Investing in hope A wealthy family fighting its own disease boosted research.. Can it spur new dementia treatments? 🗣️"Here was this beautiful family that really wanted to find a cure. And none of us scientists wanted to let them down." https://t.co/DBmpjpkxkl
Little‑Known Kymera Fact Worth Sharing Today
With Kymera in the news today, reposting this cool little known fact about them that I learned on a prior visit. https://t.co/ctlvveAlJZ
3D-Printed Scaffold + Vesicles Boost Bone Regeneration
Reprogramming of cells via a 3D printed scaffold and extracellular vesicles substantially enhances bone regeneration https://t.co/w6AyvguUjS https://t.co/R32ULM1Rzt
Eli Lilly's GLP-1 Pill Ignites Rivalry with Novo
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk https://t.co/zM6udFvuNE by Kristin Jensen $LLY $NVO #obesity
B‑cell Reboot Shows Promise Across Multiple Autoimmune Diseases
More success for rebooting B cells towards cure of different autoimmune diseases beyond lupus, MS and others https://t.co/sFGMiFeiEF https://t.co/Dbvca9eox8
AI Slashes Amgen's Drug Development Timelines up to 70%
Morgan Stanley met with Amgen (biotech) management on how AI is benefiting their workflows. Key findings: - 8%: Approximate industry drug-development success rate Amgen cited as the baseline AI could help improve. - 10–14 years: Typical drug-development cycle time Amgen cited...
Beyond T(11;14): Expanding Venetoclax Use in Myeloma
Venetoclax in myeloma: t(11;14) and what else? {Commentary} [Apr 2, 2026] Catherine Pellat-Deceunynck @BloodPortfolio https://t.co/Zar26htoUT #mmsm #PrecisionMedicine https://t.co/zm0Fv6GY2l
GSK’s Leucovorin
what a timeline - Sept. 1999 - $GSK withdraws Wellcovorin (leucovorin) bc it's not selling Sept. 2025 - GSK is told by FDA to apply for a new indication for leucovorin after an FDA review of lit. March 2026 - FDA approves...
Mixed Metastatic Sites Confound Apparent Treatment Effects
Your clinical trial baseline is a mix of liver mets, lung mets, bone mets, and primary tumors. You compare it to post-treatment samples from different sites. The "treatment effects" you find will mostly be tissue site differences. https://t.co/0PyjMM2Znl
Needham’s M&A Note Erroneously Flags LLY‑VKTX Deal
1000% certain ,Needham made a mistake in their "The Biotech M&A Landscape" note -(or maybe Viking got bought and they are the only ones that know it lol) calling out a few M&A targets and inadvertently mentioning a $LLY $VKTX...
Nasal Anti‑CD3 Cuts Neuroinflammation in Long‑COVID Mice
Our new preprint by @peowenlu @SaefIzzy @weinerlabhms and colleagues shows that nasal anti-CD3 monoclonal antibody treatment can reduce neuroinflammation in a mouse model of Long COVID, even when administered at 4 weeks after infection 🧠 https://t.co/P8FZA2XA37
Innate Pharma Poised for Breakthrough with Astra Phase III
Innate Pharma $IPH. €110m market cap, decent net cash position (runway for another few Qs), and several key drug programs reaching critical milestones. The most significant is a Phase III trial (monalizumab in lung cancer) run with Astra $AZN, with...
Next-Gen Yellow Fever Vaccine Shows Promise in Mid
My comments and interview with @Medscape Next-Gen Yellow Fever Vaccine Hits the Mark in Mid-Stage Trial https://t.co/kFfGH4c5gt
View mRNA‑CRISPR as Molecular Surgery, Not Drugs
What if we started thinking of mRNA-CRISPR gene editing as molecular surgery, not as a pharmaceutical product? Excellent @nytimes guest essay ⤵️ https://t.co/S61XwNRVZF
Rapamycin Fails to Slow Epigenetic Aging, Sinclair Concedes
David Sinclair says rapamycin had no measurable effect on slowing or reversing epigenetic aging in humans. This was a drug most of the longevity community supported. He was even a believer of it. It was found to extend lifespan in: • Inbred lab animals •...
Weight‑loss Drug Semaglutide Cuts Depression Risk by 42%
A 10-year study finds weight-loss drugs lower the risk of #depression and anxiety. Published in The Lancet Psychiatry, the #research revealed a 42% lower risk of #mentalhealth hospitalisation during periods of semaglutide use. https://t.co/CphnQl0Khx
Plan Biotech Catalysts Ahead to Capture Stock Moves
Investors should know WHAT will move a stock and WHEN, especially in biotech with the outsized moves. Build your catalyst calendar ahead of time. You won't have time to thoughtfully analyze the data when it hits #learnbiotechinvesting #biotech #investing #BiotechPrometheus https://t.co/2RGMVrR2lG
Regenerative Medicine Needs Data Over Hype
I recently had the opportunity to sit down with Scott Carney for a wide-ranging conversation on regenerative medicine, stem cells, peptides, and the growing gap between scientific promise and clinical reality. In the conversation, we dig into: – Why stem cell therapies...
Engineered Bacteria Consume Tumor Core, Overcoming Drug Barriers
JUST IN: Scientists built bacteria that EATS cancer from the inside out. The future of cancer treatment isn't a drug. It's a living organism that devours tumors from the inside. Here's how it works: Solid tumors have a dead center. No oxygen. No...
SIRT6 Gene Therapy Remains Safe, Effective in Aged Beagles
Genflow sees sustained safety and efficacy in SIRT6 beagle trial 🐶 “Genflow Biosciences reported that three-month follow-up data from its SLAB trial in aged beagles show sustained safety and efficacy of its SIRT6 centenarian gene therapy, with no adverse events and...
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/18HJ5kRuNj
Phase
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
Single Gene Therapy Dose Eradicates Brain Tumors in Mice
GENE THERAPY SAFELY ERADICATES BRAIN TUMOURS IN MICE A single dose of an innovative gene therapy could eliminate hard-to-treat brain tumours and prevent them from coming back, according to a pre-clinical trial in mice, reported in Nature. “More than 80 per cent...
Dietary Amino Acid Restriction Shows Promise Against Pediatric Brain Cancer
Can rebooting the diet, eliminating 2 essential amino acids, help treat an aggressive brain cancer in children? mechanism and potential established from experimental model https://t.co/wmAFM2ErRB https://t.co/PAOr5SL30y
AI Drug Discovery: Hype Overwhelms Real Clinical Success
AI Drug Discovery – Revolution or Expensive Illusion? | Ep. 978 https://t.co/YLQ8QNlnWv [ 00:34 ] Billions into AI drug discovery [ 01:04 ] AI doesn’t cure diseases [ 01:38 ] Expensive illusion vs reality [ 02:23 ] Original pitch inefficiency problem [ 03:48 ] Only 10...
Synthetic Biology Platform Outpaces De‑extinction Hype
Most people hear “bring back the woolly mammoth” and say, “impossible.” Colossal might be considered a de-extinction company, but Ben Lamm is actually building a synthetic biology platform with consequences that could be much bigger than bringing back mammoths. -- $10B...
New Catalyst Quickly Builds Complex Molecules for Drug Discovery
A new catalytic method enables rapid, selective synthesis of branched molecules from simple, inexpensive reagents, streamlining early drug discovery and expanding access to complex molecular architectures. drugdiscovery
Trust, Not Software, Drives GLP‑1 Startup Success
If anyone can build a GLP-1 company for $50K, what actually separates the winners? I asked Josh Tauber and @keatonbedell on Lifers, their answer: not software. Trust. WATCH/LISTEN: Spotify: https://t.co/hrs0ZbILVz Apple: https://t.co/e8IxsoZ2bB Youtube: https://t.co/ORjNyzcOli
AI-Driven Biology Faces Jagged Data Frontier; Initiative Leads
AI accelerating bio is going to be a jagged frontier driven by availability of relevant data. This is a fantastic initiative to get ahead of that. (see also what OAIF @JacobTref is doing).
Two Cancer Startups Secure $237M for Antibody Innovations
A couple cool cancer drug startups profiled this week in TR. Sidewinder Therapeutics with $137M for bispecific ADCs https://t.co/tJcQwI7C4U and Stipple Bio with $100M for novel targets for antibody drugs. https://t.co/rbXkuaRpoe
Wedbush Flags One NKTR Dosing Interval as Unviable
You'll never guess which of these two dosing intervals Wedbush says "may not be viable" for $NKTR Rezpeg moving forward. Won't mince words - This firm is responsible for the worst sellside work I've ever seen. Sorry to be harsh,...
Life Biosciences Celebrates ER-100 Milestone After Eight Years
Congrats Life Biosciences team. Big thanks to our investors. Well done Jerry McLaughlin, Michael Ringel, Amit Shashank, Sharon Rozenzweig-L, Ivan Kaplan, @chefserenapoon & team. Go ER-100🤞 Not sure we qualify as “startup” after 8 yrs & being in the clinic...
Adaptive Coherence Framework Guides Smarter Microbiome Health
We can be smarter about our microbiome health by cueing into host interactions, an "adaptive coherence framework" @cellhostmicrobe https://t.co/mprFgV7Gjq https://t.co/rQiPeK2aJP
Novo Undercuts Lilly with Pricier Wegovy; Insmed Braces for Flop
Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure https://t.co/jN9GuuOf4s $NVO $LLY $INSM $VRTX $BIIB
2024 NIA‑AA Definition Connects Biomarkers Directly to Care
The 2024 NIA-AA biological definition of Alzheimer’s disease: linking biomarkers to clinical practice https://t.co/00cP1mXXHR https://t.co/VQ59YeIUR1
Genomics Predicts Individual Weight Loss From GLP‑1 Drugs
Genomics of GLP-1 drug response and side effects With genomic and demographic data it's possible to predict magnitude of weight loss response @23andMe https://t.co/iAS2Fjjxig https://t.co/AXsWnZw2Ub
Genomic Drivers of Venetoclax Resistance in T(11;14) Myeloma
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH) [Apr 2, 2026] @MKaddouraMD et al. @lbaughn @BloodPortfolio https://t.co/qmI6giPG6K #mmsm #PrecisionMedicine https://t.co/hpwUcavTg9
RFK Jr. Pushes to Overturn Peptide Ban, Officials Dispute Claims
RFK Jr. May Reverse a Peptide Ban He Calls “Illegal.” Former FDA Officials Say He Mischaracterized Their Work. https://t.co/glqreTHvKA https://t.co/Vi4OTryX3p
Lymph-Node CD8+ T Cells Amplify PD-1 Blockade in GI Cancer
PD-1 antibody-bound progenitor-exhausted CD8+ T cells in lymph nodes boost PD-1-blockade anti-tumor immunity in gastrointestinal cancer https://t.co/VKoxzy6oUq https://t.co/cQG2sLWtL2
NRH Prevents Age‑related Hearing Loss via Sirt3‑mediated Ferroptosis Suppression
NRH attenuates age-related hearing loss by suppressing cochlear ferroptosis and cellular senescence via Sirt3 activation https://t.co/MOqQblWYNM https://t.co/uhSMXRIxDK
Controversial Drugs Once Feared, Now Offer Hope
A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope Another wonderful piece from @Jasonmmast https://t.co/zOvLrdAPKi via @statnews
Know the FDA Process: Key to Biotech Investing
Investors should understand the #FDA regulatory process well. Here is a quick summary At each step investors should ask themselves if the company is developing things in a way that will satisfy the FDA Until a drug is approved the FDA is...
